Prophylaxis plays a vital role in preventing PCP, especially in high-risk populations. TMP-SMX is the preferred prophylactic agent and has been shown to be highly effective. In HIV-infected individuals, initiating PCP prophylaxis when CD4 counts fall below 200 cells/µL is a standard practice. Prophylaxis is also recommended for certain cancer patients and organ transplant recipients.